The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
News
EMA, FDA both accept filing of Novartis’ ofatumumab
In two head-to-head studies, ofatumumab demonstrated superiority over Aubagio in patients with relapsing forms of multiple sclerosis.
‘Smart watches’ for Alzheimer’s discussed as numbers set to double by 2050
Alzheimer’s is a complex disease and one of the largest challenges facing healthcare today, with lots of failed treatments in past pipelines.
GSK recruits Clover Biopharmaceuticals in latest coronavirus effort
GSK initially announced plans to make its pandemic vaccine adjuvant platform technology available at the beginning of February.
‘Record high’ two million people at type II diabetes risk
There are 1,969,610 people registered with a GP who have non-diabetic hyperglycaemia, a condition which puts people at high risk of type II.
New AI-created antibiotic can kill many antibiotic-resistant bacteria
The AI system can screen more than a hundred million chemical compounds in a matter of days.
NHS to install ‘LIGHT’ proton therapy
In addition to the launch, Advanced Oncotherapy will work with an NHS Trust on various research and development activities associated with the use of LIGHT to increase the awareness of proton therapy for the treatment of cancer.
Galderma’s investigational prurigo nodularis drug hits Phase II endpoint
Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
Opdivo/Yervoy continues to impress in kidney cancer
The results represent the longest follow-up with any immuno-oncology–based therapy in previously untreated RCC patients.
GSK, Immatics team up for cancer cell therapies
Under the terms of the agreement, Immatics will receive an upfront payment of $45m.
NHS staff still face ‘unacceptable’ abuse from public
NHS leaders have confirmed that from April, NHS services will be able to protect staff by barring from non-emergency care any patient or visitor who inflicts discriminatory or harassing behaviour on staff.
Teva’s Austedo flunks in late-stage paediatric Tourette study
Compared to placebo, the drug didn’t achieve significant reduction in motor and phonic tics.
Half of GPs skip out ‘vital’ diabetes kidney test
The test, which is used to detect kidney damage that can lead to fatal complications, should be conducted every year.
Roche’s Tecentriq bags Priority Review in US
In a trial, the drug improved overall survival by 7.1 months compared with chemotherapy.
US breakthrough designation granted to Padcev in bladder cancer
The designation was granted based on results from the dose-escalation cohort and expansion cohort A of the EV-103 Phase Ib/II trial.
